首页> 外文会议>Biomedical Engineering and Biotechnology (iCBEB), 2012 International Conference on >Development of TNF-alpha Inhibitor Drugs in Treatment of Rheumatoid Arthritis
【24h】

Development of TNF-alpha Inhibitor Drugs in Treatment of Rheumatoid Arthritis

机译:TNF-α抑制剂在类风湿关节炎治疗中的应用

获取原文
获取原文并翻译 | 示例

摘要

Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease that principally attacks synovial joints. Patients with RA suffer pain and physical disability. Therefore, scientists are developing many therapies to conquer this disease. Tumor necrosis factor alpha (TNF-a) is one of the key pro-inflammatory cytokine in attending and mediating the inflammatory process of RA. Thus, scientists are trying to develop the drugs targeting at TNF-a for the treatment of RA and have achieved satisfied results in theory and clinical practices. Biological inhibitors are in the lead to be approved to the market. However, the following researches reveal the side effects of this kind of drugs. On the other hand, the small molecular inhibitors are discovered and developed by the scientists, which show great prospects in the treatment of RA. In this review, we will have a brief introduction and outlooks of biological and small molecule TNF-a inhibitors.
机译:类风湿关节炎(RA)是一种慢性全身性自身免疫性疾病,主要攻击滑膜关节。 RA患者会遭受疼痛和身体残疾。因此,科学家正在开发许多疗法来克服这种疾病。肿瘤坏死因子α(TNF-a)是参与和介导RA炎症过程的关键促炎细胞因子之一。因此,科学家们正在尝试开发针对TNF-α的用于RA的药物,并在理论和临床实践中取得了令人满意的结果。生物抑制剂率先被批准进入市场。但是,以下研究揭示了这种药物的副作用。另一方面,小分子抑制剂是科学家发现和开发的,在RA的治疗中显示出广阔的前景。在这篇综述中,我们将简要介绍生物和小分子TNF-α抑制剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号